The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People
NCT04658433 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2022-02-24
Summary
The Renin-Angiotensin-Aldosterone System (RAAS) is involved in blood pressure regulation and electrolyte balance. Angiotensin-converting enzyme (ACE) is a critical regulator of RAAS by cleaving angiotensin (Ang1) to Angiotensin2 (Ang2), which is the most powerful biologically active product of RAAS \[1\]. In the same context, angiotensin-converting enzyme 2 (ACE2) converts Ang2 to Ang (1-7), which is a vasodilator, antithrombotic, and antihypertrophic peptide \[2\]. ACE2 which is found in many tissues \[3\] has opposite effects to ACE on the heart, kidneys, and lungs \[4\]. Many pathological conditions, in particular cardiovascular disease (CVD), have shown a link between a disturbance in ACE/ACE2 ratio and the downregulation of ACE2 levels \[5\]. Also, ACE/ACE2 has been reported to be higher in moderate to severe chronic heart failure \[6\] as well as systolic blood pressure \[7\]. Recently, an elevated ACE/ACE2 ratio is linked to Coronavirus disease 2019 (COVID-19). SARS-COV2 enters target cells by binding of the spike protein to ACE2 and a specific transmembrane serine protease 2 (TMPRSS2) for the spike (S) protein priming, which also leads to downregulation of ACE2 \[8\]. Down-regulation of ACE2 caused by Coronavirus may have a potential role in the pathogenesis of COVID-19 infection. Accordingly, people with a higher ACE/ACE2 ratio may be more at increased risk of worse Covid-19 consequences \[9\].
On the other hand, omega-3 fatty acids could decrease CVD risk by their anti-inflammatory anti-thrombotic function \[10\]. A meta-analysis comprising 15,806 patients, showed that omega-3 fatty acids associated with a 30% reduction in fatal myocardial infarction and sudden death, in addition to a 20% reduction in overall mortality \[11\]. To the best of our knowledge, no clinical trials have evaluated the effect of omega-3 supplementation on serum ACE/ACE2 ratio which is recently ascribed as a potential key in 2019 Covid-19 as well as CVD \[5,9\].
Conditions
- Cardiovascular Risk Factor
- Covid19
Interventions
- DIETARY_SUPPLEMENT
-
300 mg of omega3-FA
The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
Sponsors & Collaborators
-
Applied Science Private University
lead OTHER
Principal Investigators
-
Mahmoud S Abu-Samak, PhD · Department of Clinical Pharmacy and Therapeutics , Applied Science Private University, Amman -Jordan
-
Sara M Daboul, MSC · Department of Clinical Pharmacy and Therapeutics , Applied Science Private University, Amman -Jordan
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-03-05
- Primary Completion
- 2021-12-20
- Completion
- 2022-02-10
Countries
- Jordan
Study Locations
More Related Trials
-
Omega-3 Oil Use in COVID-19 Patients in Qatar
NCT04836052 ·Status: UNKNOWN ·Phase: PHASE3
-
Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD.
NCT02092584 ·Status: COMPLETED ·Phase: PHASE4
-
Plasma Diurnal Variation in and Absorption of EPA and DHA
NCT02661698 ·Status: COMPLETED ·Phase: NA
-
The Effect of Omega-3 Supplementation on Muscle Functioning, Inflammation and Muscle Signaling
NCT03986307 ·Status: COMPLETED ·Phase: NA
-
Uptake of an Omega-3 Oil in Healthy Adults
NCT05650294 ·Status: COMPLETED ·Phase: NA
-
Bioavailability of Omega-3 Fatty Acids From Fish Oil Supplements
NCT06665464 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Supplement and Health Markers
NCT06492694 ·Status: COMPLETED ·Phase: NA
-
Omega-3-Index Response to Eating Poultry Foods Naturally Enriched With Omega-3 Polyunsaturated Fatty Acids
NCT06259825 ·Status: RECRUITING ·Phase: NA
-
Cardiometabolic Benefits of Omega-3 Polyunsaturated Fatty Acids
NCT03378232 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Fatty Acids and Muscle Protein Synthesis
NCT00794079 ·Status: COMPLETED ·Phase: NA
-
A Study to Determine Optimal Absorption of Single Dose Omega-3
NCT05491759 ·Status: COMPLETED ·Phase: PHASE4
-
A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA
NCT06629103 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?
NCT01699230 ·Status: UNKNOWN ·Phase: PHASE3
-
The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity
NCT01692431 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis
NCT00886704 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Fatty Acid Supplementation to Enhance Performance
NCT05924139 ·Status: COMPLETED ·Phase: NA
-
Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement
NCT06802068 ·Status: COMPLETED ·Phase: NA
-
Fish Oil and Cardiovascular Suboptimal Health
NCT02103517 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Omega 3 in Hypertensive Patients
NCT06840964 ·Status: COMPLETED ·Phase: NA
-
Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes
NCT02610270 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Vascular Impact of Omega-3 in Metabolic Syndrome
NCT01566188 ·Status: COMPLETED ·Phase: NA
-
Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD
NCT02117960 ·Status: COMPLETED ·Phase: PHASE4
-
Plasma Level of Various Omega-3 Lipids
NCT03118999 ·Status: COMPLETED ·Phase: NA
-
Diet and Omega-3 Intervention Trial on Atherosclerosis
NCT00764010 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface
NCT02295358 ·Status: WITHDRAWN